Safety and Efficacy of Umbilical Cord Blood-Derived Mesenchymal Stem Cells in the Treatment of Long-Term Cytopenia After CAR-T Therapy
Trial Parameters
Brief Summary
This study is a single arm, open label, exploratory clinical study aimed at evaluating the efficacy, and safety of allogeneic umbilical cord blood-derived mesenchymal stem cells in the treatment of long-term cytopenia after CAR-T therapy.
Eligibility Criteria
Inclusion Criteria Patients must meet all the following criteria to be enrolled in this study: * 1.Voluntarily participate in the study and sign the informed consent form; * 2.Aged ≥ 18 years, regardless of gender; * 3.Patients with acute lymphoblastic leukemia (ALL), lymphoma, or myeloma who still have severe cytopenia (meeting any of the following conditions: absolute neutrophil count ≤ 1×10⁹/L; platelet count ≤ 30×10⁹/L; hemoglobin ≤ 70 g/dL) 3 weeks after CAR-T cell infusion; * 4.ECOG performance status score ≤ 2; * 5.Estimated survival time ≥ 6 months; * 6.For female patients of childbearing potential, a negative pregnancy test result is required. Female patients of childbearing potential and male patients must use highly effective contraceptive measures during the study period and for 4 months/6 months after the discontinuation of treatment, respectively. Exclusion Criteria Patients with any of the following conditions are prohibited from enrolling in this study: * 1.Having recei